Welcome to our dedicated page for Usana Health Sciences SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. (NYSE: USNA) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its nutrition-focused business, financial condition, and governance. This page centralizes those SEC filings and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
USANA’s current reports on Form 8-K include disclosures about preliminary financial results, updated net sales guidance, and leadership transitions, such as changes in the Chief Executive Officer role. Other 8-K filings describe credit agreements, financial covenants, and the posting of Management Commentary documents and conference call details related to quarterly results. These filings complement the company’s earnings releases and provide context on how management views performance in its direct selling and direct-to-consumer segments.
Investors can also use this page to access USANA’s periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, where available. These documents typically contain segment information, risk factor discussions, and explanations of non-GAAP measures such as Adjusted EBITDA and Adjusted diluted earnings per share, which USANA references in its communications.
Stock Titan’s platform enhances these filings with AI-generated highlights that explain key sections, summarize complex tables, and surface notable items such as changes in outlook, capital structure, or significant agreements. Users can quickly locate information on topics like net sales trends, credit facilities, or integration costs related to acquisitions such as Hiya, and can review insider-related disclosures when Forms 3, 4, or 5 are filed. Real-time updates from EDGAR help ensure that new USANA filings appear promptly with concise explanations.
USANA Health Sciences chief information officer Peter Benedict reported equity award activity involving restricted stock units and common shares. On February 27, 2026, he exercised 3,906 restricted stock units, each convertible into one share of USANA common stock, and received 3,906 common shares at a stated price of $0.0000 per share. To cover tax obligations from this vesting, 1,174 common shares were disposed of through a tax-withholding transaction at $21.52 per share. After these transactions, Benedict directly held 38,602 restricted stock units and 4,553 common shares of USANA. The restricted stock units represent a contingent right to receive one share of common stock each and vest 25% on the anniversary of February 27, 2025.
USANA Health Sciences chief scientific officer Kathryn Michelle Armstrong reported equity award activity involving restricted stock units and common stock. She exercised or converted 4,190 restricted stock units into the same number of common shares at a stated price of $0.00 per share.
On the same date, 2,015 common shares were disposed of at $21.52 per share to satisfy tax obligations through share withholding, rather than an open‑market sale. After these transactions, she directly owned 2,823 shares of USANA common stock, and 40,592 restricted stock units remained following the derivative transaction.
USANA Health Sciences chief legal officer Joshua Foukas reported two transactions involving company equity. On February 19, 2026, he acquired 36,662 restricted stock units, each representing a right to receive one share of USANA common stock, bringing his RSU holdings to 73,270 units. On February 20, 2026, he executed an open-market sale of 4,461 shares of common stock at an average price of $21.345 per share, after which his directly held common stock position was reported as 0 shares.
Benedict Peter reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences reported that its Chief Information Officer, Peter Benedict, received a grant of 21,775 Restricted Stock Units (RSUs) on February 19, 2026. Each RSU represents a contingent right to receive one share of USANA common stock.
The grant vests in four equal installments of 25% on each February 19 after the grant date, aligning the executive’s compensation with the company’s long-term performance. Following this award, Benedict directly holds 42,508 RSUs in total.
Armstrong Kathryn Michelle reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences chief scientific officer Kathryn Michelle Armstrong received a grant of 24,526 restricted stock units on February 19, 2026. Each unit represents a contingent right to receive one share of USANA common stock. After this grant, she beneficially owns 44,782 restricted stock units directly. The units vest in four equal 25% installments on each February 19 following the grant date.
Noot Walter reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences chief operating officer Walter Noot received a grant of 41,373 restricted stock units on February 19, 2026. Each unit represents the right to receive one share of USANA common stock and vests 25% on each following February 19. After this award, he directly holds 82,552 restricted stock units.
USANA Health Sciences reported that Chief Commercial Officer Brent Neidig acquired 37,610 restricted stock units on February 19, 2026 as a grant. Each unit represents a contingent right to receive one share of USANA common stock. Following this award, Neidig directly holds 74,194 restricted stock units. The grant is scheduled to vest 25% on each February 19 after the grant date.
USANA Health Sciences reported that Chief People Officer Paul A. Jones acquired 25,622 restricted stock units on February 19, 2026 as a grant or award. Each restricted stock unit represents a contingent right to receive one share of USANA common stock. The grant vests in four equal installments of 25% on each February 19 after the grant date. Following this award, Jones holds 51,207 restricted stock units directly.
IIEKKING G DOUG reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences reported that its Chief Financial Officer, Doug G. Iieekking, received a grant of 41,639 restricted stock units on February 19, 2026. Each restricted stock unit represents a contingent right to receive one share of USANA common stock.
The award vests in stages, with 25% of the units vesting on each 19th of February thereafter. Following this grant, the officer directly holds 83,218 restricted stock units, aligning a portion of his compensation with the company’s future share performance.
USANA Health Sciences CEO Kevin Guest reported an equity award. On February 19, 2026, he acquired 82,726 restricted stock units at a stated price of $0.00 per unit. Each unit is a contingent right to receive one share of USANA common stock.
The restricted stock units vest 25% on each 19th of February thereafter under the grant terms. Following this award, Guest directly held a total of 135,062 restricted stock units in USANA.